Thyme Care raises Series E led by Morgan Health at 16 times revenue, with Humana and CVS Health Ventures joining

Buy versus build here turns on a denominator. Revenue passed $125m last year ^[9] against the more than $7bn of oncology spend the company says it manages ^[3], which is 1.8 cents of fee per dollar of claims moving through the model ^[13]. What that fee is meant to buy, on the company's own account, is a validated 5 to 10 percent reduction in total cost of care ^[11], or $350m to $700m on a $7bn base ^[14], which is 2.8 to 5.6 times the fee itself ^[15]. A payer staring at that ratio can build its own navigation network across all 50 states ^[3] and carry the fixed cost against one book of members, or it can write a check into infrastructure whose per-member cost falls every time another plan routes through it. Humana and CVS Health Ventures chose the second, alongside Morgan Health as lead ^[1] and, per the company, community oncology practices and health systems ^[5].

The price is the better puzzle, or rather the change in the price. More than $2bn on $125m of revenue is about 16 times ^[19]; the Series D, which CNBC reports was struck at roughly half that mark less than a year ago ^[8], implies something near $1bn on a revenue base of about $25m, if last year really was five times the prior one ^[9][16], and that is closer to 40 times ^[17]. Revenue grew fivefold and the valuation doubled ^[9][8]. For a business launched in 2020 ^[10], that is the trade a profitable company makes when it does not need the money.

And it does not. At more than $2bn post-money, $125m is under 6.3 percent of the equity ^[20], sold by a company that says it is profitable with positive free cash flow and a large balance sheet ^[6]. The allocation question is where it goes, and the answer is not deeper penetration of the 10.5 million people who can already reach the service ^[3]. It goes into Thyme Companies, a new parent entity that intends to spin up separate businesses in biosimilar adoption and clinical trial accrual, the first later this year ^[4], plus acquisitions and hiring ^[12]. Robin Shah, who stepped down as Thyme Care's chief executive in July ^[21] and now chairs the parent while Brad Diephuis runs the operating company ^[7], says there is no near-term view on an IPO ^[12].

This is probably wrong, but the reading I would defend is that the 5 to 10 percent is a multi-payer artifact, cheaper to rent at 1.8 percent of spend ^[13] than to reproduce inside one plan. There are a few ways that reading could give out. The savings figure is the company's, described as validated with no validator named ^[11], and if an independent count lands nearer 2 percent then the renewal talks and the $2bn move together. A sub-6-percent slug through a ventures arm ^[20] is ordinary portfolio behaviour rather than a sourcing decision, and the mark was set with institutional co-investors in the room ^[2]. And $7bn across 10.5 million lives is about $667 a head ^[18], which looks like the whole oncology claim line of a covered population rather than a managed subset, so "manages" is carrying weight the announcement never defines ^[3]. Of the two numbers this round is priced off, only the fee is one a payer can verify from its own claims file.